Iovance
Philadelphia, US · 1 known investors
Iovance develops T-cell-based immunotherapies, including tumor-infiltrating lymphocyte (TIL) therapies and genetically modified TIL therapies, designed to target neoantigens unique to each patient's tumor. The company focuses on treating advanced solid tumor cancers and manufactures its therapies at its Cell Therapy Center in Philadelphia.
Investors · 1
Frequently asked questions
- What does Iovance do?
- Iovance develops T-cell-based immunotherapies, including tumor-infiltrating lymphocyte (TIL) therapies and genetically modified TIL therapies, designed to target neoantigens unique to each patient's tumor. The company focuses on treating advanced solid tumor cancers and manufactures its therapies at its Cell Therapy Center in Philadelphia.
- Who are Iovance's investors?
- Iovance's investors include Avoro Capital Advisors.
- Where is Iovance headquartered?
- Iovance is headquartered in Philadelphia, US.